Halberd Corp.

Develop extra-corporeal treatments of disease

Recent News

  • Halberd Enters Strategic Alliance for Longevity, Alzheimer's Disease, and Cancer Early Detection, Prevention and Treatment

    Jackson Center, Pennsylvania--(Newsfile Corp. - September 27, 2022) - Halberd Corporation (OTC Pink: HALB) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named "ExtendalifeTM". The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer's Disease and Cancer treatments using the combined patented and patent-pending technologies of the alliance member companies. The subsidiary will be staffed by...

    2022-09-27 8:00 AM EDT
  • Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein

    Jackson Center, Pennsylvania--(Newsfile Corp. - August 23, 2022) - Halberd Corporation (OTC Pink: HALB) researchers have demonstrated the ability to precisely control the level of PD-1 in human blood serum in laboratory in-vitro testing. PD-1 (programmed cell death-1) is a T-Cell protein which can be used by tumor cells to fool the body's immune system into allowing the tumor to grow1. Halberd's extracorporeal process, operating on blood serum, can potentially be used to eliminate PD-1 and allow the...

    2022-08-23 8:00 AM EDT
  • NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology

    Jackson Center, Pennsylvania--(Newsfile Corp. - August 4, 2022) - Halberd Corporation (OTC Pink: HALB) has received a letter of endorsement from Carl Eller, President of the NFL Retired Players Association (NFL RPA), for Halberd's research work in the development of treatments for Traumatic Brain Injury (TBI)/chronic traumatic encephalopathy (CTE) sustained by current and retired players. Traumatic brain injuries often progress to neurodegenerative diseases, such as PTSD, Alzheimer's Disease, Parkinson's Disease, Epilepsy and suicide ideation.

    2022-08-04 8:00 AM EDT
  • Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary

    Jackson Center, Pennsylvania--(Newsfile Corp. - July 20, 2022) - Halberd Corporation (OTC Pink: HALB) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd's patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and health-related illnesses. For now, the new entity will be staffed by Halberd personnel until such time as business opportunities arise and appropriately skilled individuals are recruited to carry the subsidiary forward in its...

    2022-07-20 8:00 AM EDT
  • Halberd's Antibody Effective Against All 4 SARS-CoV-2 Mutations, Including Omicron

    Jackson Center, Pennsylvania--(Newsfile Corp. - July 14, 2022) - Halberd Corporation (OTC Pink: HALB) researchers developed, with appropriate protocols, a SARS-CoV-2 antibody effective against all four Covid-19 mutations currently in circulation, including Omicron. When Halberd's antibody was combined with a leading commercially available Covid-19 antibody in an antibody cocktail, effectiveness of the commercial antibody was increased from 65% to 94%. This could lead to a treatment that is widely effective against existing and future mutations of SARS-CoV-2.Dr. Mitchell...

    2022-07-14 8:00 AM EDT
  • Halberd Corporation Update, CEO Letter and 2022 Expectations

    Jackson Center, Pennsylvania--(Newsfile Corp. - July 12, 2022) - Halberd Corporation (OTC Pink: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. The accomplishments for the Second Quarter ending June 30, 2022, are as follows:2Q ACHIEVEMENTSAdded an animal testing expert (DVM/PhD) to our list of scientific consultants to plan and execute extensive animal testing of Halberd's patented extracorporeal process for the removal of targeted disease antigens.Our first scientific article on our...

    2022-07-12 8:00 AM EDT
  • Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

    Jackson Center, Pennsylvania--(Newsfile Corp. - June 21, 2022) - Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC Pink: HALB) announced the creation of a subgroup of researchers to focus on cancer treatment. Halberd's technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments.The subgroup will be guided by Halberd's existing technical team members, but will add the necessary expertise to carry the...

    2022-06-21 9:01 AM EDT
  • Halberd Corp. and Mississippi State University Discuss Animal Testing as Prelude to FDA Certification

    Jackson Center, Pennsylvania--(Newsfile Corp. - June 8, 2022) - Halberd Corporation (OTC Pink: HALB) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd's patented extracorporeal disease eradication processes. Consistent with the press release of May 18, 2022, the Company has commenced its pursuits with mdi Consultants, Inc, an FDA application consulting firm, and the FDA to determine specific animal testing requirements. Animal testing...

    2022-06-08 8:00 AM EDT